<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00535366</url>
  </required_header>
  <id_info>
    <org_study_id>1249.1</org_study_id>
    <secondary_id>Eudract2007-003169-42</secondary_id>
    <nct_id>NCT00535366</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Comparison of Steroid or Placebo in Combination With Salmeterol and Tiotropium in COPD</brief_title>
  <official_title>A Randomised, Phase II, Double-Blind, Double-Dummy, Four-period Crossover Efficacy and Safety Comparison of 4-Week Treatment Periods of Blinded Fluticasone (500 mcg Bid, MDI), Ciclesonide (400 mcg qd, MDI), Ciclesonide (800 mcg qd, MDI) or Placebo in Free Combination With Open-Label Tiotropium (18 mcg qd, HandiHaler) and Salmeterol (50 mcg Bid, Diskus) in Patients With COPD.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      This efficacy and safety study compares four different combinations of blinded inhaled
      steroid treatments on top of open-label tiotropium and salmeterol in patients with chronic
      obstructive pulmonary disease (COPD). The primary objective is the effect on lung function
      parameters.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Trough FEV1 response at the end of each 4 week period of randomised treatment</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Trough forced vital capacity (FVC) response after 4 weeks of each blinded treatment</measure>
    <time_frame>after 4 weeks of each blinded treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All adverse events</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse rate and blood pressure (seated)</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 and FVC morning peak response</measure>
    <time_frame>day 1 and day 28 of each blinded treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 and FVC evening peak response</measure>
    <time_frame>day 1 and day 28 of each blinded treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 AUC (0-3h), after 4 weeks of each blinded treatment</measure>
    <time_frame>after 4 weeks of each blinded treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 AUC (12-15h) after 4 weeks of each blinded treatment</measure>
    <time_frame>after 4 weeks of each blinded treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC AUC (0-3h) after 4 weeks of each blinded treatment</measure>
    <time_frame>after 4 weeks of each blinded treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC AUC (12-15h) after 4 weeks of each blinded treatment</measure>
    <time_frame>after 4 weeks of each blinded treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough and peak inspiratory capacity (IC) and vital capacity (VC) response in the morning of day 1 and at day 28 of each treatment period</measure>
    <time_frame>day 1 and day 28 of each blinded treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weekly mean pre-dose morning and evening peak expiratory flow (PEF)</measure>
    <time_frame>28 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weekly mean number of occasions of rescue therapy used per day</measure>
    <time_frame>28 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mahler Dyspnea Indices (TDI) collected at the end of each treatment period and each wash-out period</measure>
    <time_frame>28 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fractional exhaled nitric oxide after 4 weeks of each blinded treatment</measure>
    <time_frame>after 4 weeks of each blinded treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">103</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>Tiotropium+salmeterol+fluticasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Tiotropium+salmeterol+ciclesonide low</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Tiotropium+salmeterol+ciclesonide high</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium</intervention_name>
    <description>Oral inhalation by HandiHaler® device</description>
    <arm_group_label>Tiotropium+salmeterol+fluticasone</arm_group_label>
    <arm_group_label>Tiotropium+salmeterol+ciclesonide low</arm_group_label>
    <arm_group_label>Tiotropium+salmeterol+ciclesonide high</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salmeterol</intervention_name>
    <description>Oral inhalation from Diskus®</description>
    <arm_group_label>Tiotropium+salmeterol+fluticasone</arm_group_label>
    <arm_group_label>Tiotropium+salmeterol+ciclesonide low</arm_group_label>
    <arm_group_label>Tiotropium+salmeterol+ciclesonide high</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluticasone</intervention_name>
    <description>Oral inhalation from metered dose inhaler (MDI)</description>
    <arm_group_label>Tiotropium+salmeterol+fluticasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciclesonide low</intervention_name>
    <description>Oral inhalation from MDI</description>
    <arm_group_label>Tiotropium+salmeterol+ciclesonide low</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciclesonide high</intervention_name>
    <description>Oral inhalation from MDI</description>
    <arm_group_label>Tiotropium+salmeterol+ciclesonide high</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral inhalation from MDI</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Relatively stable, moderate to severe COPD

          -  Male or female patients 40 years of age or older.

          -  Current or ex-smokers with a smoking history of more than 10 pack years

        Exclusion Criteria:

          -  Other significant disease that can influence the study results or be a safety risk for
             the patient

          -  Other medication that can influence the study results

          -  Hypersensitivity to the study medication

          -  Patients with unstable COPD
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1249.1.32003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Genk</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1249.1.32001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1249.1.32002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hasselt</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1249.1.32004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oostende</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1249.1.45001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aarhus C</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1249.1.49001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Großhansdorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1249.1.49002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1249.1.49003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Weinheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1249.1.31002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1249.1.31003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Harderwijk</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1249.1.31001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Heerlen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1249.1.31004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Veldhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 25, 2007</study_first_submitted>
  <study_first_submitted_qc>September 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2007</study_first_posted>
  <disposition_first_submitted>April 30, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>May 22, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 30, 2014</disposition_first_posted>
  <last_update_submitted>May 22, 2014</last_update_submitted>
  <last_update_submitted_qc>May 22, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 30, 2014</last_update_posted>
  <responsible_party>
    <name_title>Boehringer Ingelheim, Study Chair</name_title>
    <organization>Boehringer Ingelheim</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Tiotropium Bromide</mesh_term>
    <mesh_term>Salmeterol Xinafoate</mesh_term>
    <mesh_term>Ciclesonide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

